» Articles » PMID: 36191176

Effectiveness of Mental Health Apps for Distress During COVID-19 in US Unemployed and Essential Workers: Remote Pragmatic Randomized Clinical Trial

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: During the COVID-19 pandemic, the general public was concerned about the mental health impacts of unemployment due to COVID-19 and the stress essential workers experienced during this time. Several reports indicated that people in distress were turning to digital technology, but there was little evidence about the impact of these tools on mitigating distress.

Objective: This study seeks to determine the acceptability, feasibility, usability, and effectiveness of mobile mental health apps for decreasing mental health symptoms in essential workers and unemployed individuals with suicide risk.

Methods: We recruited participants who indicated that they were unemployed because of COVID-19 or were COVID-19-designated essential workers. Participants were randomized to 1 of 4 free commercial mobile apps for managing distress that were (1) highly rated by PsyberGuide and (2) met the criteria for intervention features these participants indicated were desirable in a previous survey. Participants used the apps for 4 weeks and completed baseline and 4-week self-assessments of depression, anxiety emotional regulation, and suicide risk.

Results: We found no differences between the apps in any outcome but did find significant changes in depression and anxiety over time (Patient Health Questionnaire [PHQ]-9: estimate=-1.5, SE 0.2, 95% CI -1.1 to -1.8, P<.001; Generalized Anxiety Disorder Scale [GAD]-7: estimate=-1.3, SE 0.2, 95% CI -1.0 to -1.6, P<.001). We found no significant changes in suicidal behavior (Suicide Behaviors Questionnaire-Revised [SBQ-R]) or emotional regulation (Difficulties in Emotion Regulation Scale - Short Form [DERS-SF]) for the 4 weeks. We did find a significant dose-response pattern for changes in depression and anxiety. Using the app at least once a week resulted in greater improvements in treatment conditions over time on depression (estimate=-0.6, SE 0.2, 95% CI 1.0-0.2, P=.003) and anxiety (estimate=0.1, SE 0.2, 95% CI 0.4-0.6, P=.78). There was no association between app frequency and changes in suicidal behavior (SBQ-R) or emotional regulation (DERS-SF). We further found a significant difference between the conditions with regard to app usability, with the control app being the most usable (mean 72.9, SD 16.7; mean 71.2, SD 15.4; mean 66.8, SD 17.3; mean 65.2, SD 17.7). We found no significant differences for app acceptability or appropriateness.

Conclusions: Few studies have evaluated prospectively the utility and usability of commercial apps for mood. This study found that free, self-guided commercial mobile mental health apps are seen as usable, but no one app is superior to the other. Although we found that regular use is indicated for effects on depression and anxiety to occur in those who are more symptomatic, regression to the mean cannot be ruled out.

Trial Registration: ClinicalTrials.gov NCT04536935; https://tinyurl.com/mr36zx3s.

Citing Articles

Improving Mental Health and Well-Being Through the Paradym App: Quantitative Study of Real-World Data.

Metaxa A, Liverpool S, Eisenstadt M, Pollard J, Carlsson C JMIR Form Res. 2025; 9:e68031.

PMID: 39848610 PMC: 11803330. DOI: 10.2196/68031.


Efficacy of a Mobile App-Based Behavioral Intervention (DRIVEN) to Help Individuals With Unemployment-Related Emotional Distress Return to Work: Protocol for a Randomized Controlled Trial.

Danielson E, Saturday M, Leonard S, Levit A, Graham A, Marquez M JMIR Res Protoc. 2024; 13:e62715.

PMID: 39589786 PMC: 11632284. DOI: 10.2196/62715.


Efficacy of BrighterSide, a Self-Guided App for Suicidal Ideation: Randomized Controlled Trial.

Josifovski N, Torok M, Batterham P, Wong Q, Beames J, Theobald A JMIR Ment Health. 2024; 11:e55528.

PMID: 38551212 PMC: 11004607. DOI: 10.2196/55528.


Meta-Analysis of Studies on the Effects of Digital Therapeutics.

Seo Y, Yong S, Choi W, Kim S J Pers Med. 2024; 14(2).

PMID: 38392592 PMC: 10890481. DOI: 10.3390/jpm14020157.


Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments.

Lenze E, Torous J, Arean P Neuropsychopharmacology. 2023; 49(1):205-214.

PMID: 37550438 PMC: 10700595. DOI: 10.1038/s41386-023-01664-7.

References
1.
Schlosser D, Campellone T, Truong B, Anguera J, Vergani S, Vinogradov S . The feasibility, acceptability, and outcomes of PRIME-D: A novel mobile intervention treatment for depression. Depress Anxiety. 2017; 34(6):546-554. PMC: 5634707. DOI: 10.1002/da.22624. View

2.
Terry N, Gunter T . Regulating mobile mental health apps. Behav Sci Law. 2018; 36(2):136-144. DOI: 10.1002/bsl.2339. View

3.
Moberg C, Niles A, Beermann D . Guided Self-Help Works: Randomized Waitlist Controlled Trial of Pacifica, a Mobile App Integrating Cognitive Behavioral Therapy and Mindfulness for Stress, Anxiety, and Depression. J Med Internet Res. 2019; 21(6):e12556. PMC: 6592477. DOI: 10.2196/12556. View

4.
Pratap A, Renn B, Volponi J, Mooney S, Gazzaley A, Arean P . Using Mobile Apps to Assess and Treat Depression in Hispanic and Latino Populations: Fully Remote Randomized Clinical Trial. J Med Internet Res. 2018; 20(8):e10130. PMC: 6107735. DOI: 10.2196/10130. View

5.
Tsaousides T, Spielman L, Kajankova M, Guetta G, Gordon W, Dams-OConnor K . Improving Emotion Regulation Following Web-Based Group Intervention for Individuals With Traumatic Brain Injury. J Head Trauma Rehabil. 2017; 32(5):354-365. DOI: 10.1097/HTR.0000000000000345. View